251 related articles for article (PubMed ID: 19317448)
1. Binding epitopes and interaction structure of the neuroprotective protease inhibitor cystatin C with beta-amyloid revealed by proteolytic excision mass spectrometry and molecular docking simulation.
Juszczyk P; Paraschiv G; Szymanska A; Kolodziejczyk AS; Rodziewicz-Motowidlo S; Grzonka Z; Przybylski M
J Med Chem; 2009 Apr; 52(8):2420-8. PubMed ID: 19317448
[TBL] [Abstract][Full Text] [Related]
2. Interaction of serum amyloid A with human cystatin C--identification of binding sites.
Spodzieja M; Szymańska A; Kołodziejczyk A; Prądzińska M; Maszota M; Stefanowicz P; Szewczuk Z; Grubb A; Czaplewska P
J Mol Recognit; 2012 Oct; 25(10):513-24. PubMed ID: 22996594
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of C-terminal, β-amyloid peptide binding fragment of neuroprotective protease inhibitor, cystatin C.
Spodzieja M; Kalejta K; Kołodziejczyk AS; Maszota-Zieleniak M; Rodziewicz-Motowidło S; Żmudzińska W; Czaplewska P
J Mol Recognit; 2017 Feb; 30(2):. PubMed ID: 27714883
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune response to fibrillar beta-amyloid peptide.
Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
[TBL] [Abstract][Full Text] [Related]
5. Epitope structure and binding affinity of single chain llama anti-β-amyloid antibodies revealed by proteolytic excision affinity-mass spectrometry.
Paraschiv G; Vincke C; Czaplewska P; Manea M; Muyldermans S; Przybylski M
J Mol Recognit; 2013 Jan; 26(1):1-9. PubMed ID: 23280612
[TBL] [Abstract][Full Text] [Related]
6. Linear epitope mapping by native mass spectrometry.
Lu X; DeFelippis MR; Huang L
Anal Biochem; 2009 Dec; 395(1):100-7. PubMed ID: 19698694
[TBL] [Abstract][Full Text] [Related]
7. Interaction structure of the complex between neuroprotective factor humanin and Alzheimer's β-amyloid peptide revealed by affinity mass spectrometry and molecular modeling.
Maftei M; Tian X; Manea M; Exner TE; Schwanzar D; von Arnim CA; Przybylski M
J Pept Sci; 2012 Jun; 18(6):373-82. PubMed ID: 22522311
[TBL] [Abstract][Full Text] [Related]
8. Identification of the epitope for anti-cystatin C antibody.
Sladewska A; Szymańska A; Kordalska M; Lewandowska A; Kołodziejczyk AS; Paraschiv G; Przybylski M; Czaplewska P
J Mol Recognit; 2011; 24(4):687-99. PubMed ID: 21584879
[TBL] [Abstract][Full Text] [Related]
9. Design of peptides that form amyloid-like fibrils capturing amyloid beta1-42 peptides.
Sato J; Takahashi T; Oshima H; Matsumura S; Mihara H
Chemistry; 2007; 13(27):7745-52. PubMed ID: 17605154
[TBL] [Abstract][Full Text] [Related]
10. Interaction of serum amyloid A with human cystatin C--assessment of amino acid residues crucial for hCC-SAA formation (part II).
Spodzieja M; Rafalik M; Szymańska A; Kołodziejczyk AS; Czaplewska P
J Mol Recognit; 2013 Sep; 26(9):415-25. PubMed ID: 23836469
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen exchange studies on Alzheimer's amyloid-beta peptides by mass spectrometry using matrix-assisted laser desorption/ionization and electrospray ionization.
Kraus M; Bienert M; Krause E
Rapid Commun Mass Spectrom; 2003; 17(3):222-8. PubMed ID: 12539188
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity.
Ciaccio C; Tundo GR; Grasso G; Spoto G; Marasco D; Ruvo M; Gioia M; Rizzarelli E; Coletta M
J Mol Biol; 2009 Feb; 385(5):1556-67. PubMed ID: 19073193
[TBL] [Abstract][Full Text] [Related]
13. Structure of amyloid beta fragments in aqueous environments.
Takano K; Endo S; Mukaiyama A; Chon H; Matsumura H; Koga Y; Kanaya S
FEBS J; 2006 Jan; 273(1):150-8. PubMed ID: 16367755
[TBL] [Abstract][Full Text] [Related]
14. Domain swapping in N-truncated human cystatin C.
Janowski R; Abrahamson M; Grubb A; Jaskolski M
J Mol Biol; 2004 Jul; 341(1):151-60. PubMed ID: 15312769
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis.
Hochleitner EO; Borchers C; Parker C; Bienstock RJ; Tomer KB
Protein Sci; 2000 Mar; 9(3):487-96. PubMed ID: 10752610
[TBL] [Abstract][Full Text] [Related]
16. Structure and orientation of peptide inhibitors bound to beta-amyloid fibrils.
Chen Z; Krause G; Reif B
J Mol Biol; 2005 Dec; 354(4):760-76. PubMed ID: 16271725
[TBL] [Abstract][Full Text] [Related]
17. Qualitative and quantitative characterization of the amyloid beta peptide (Abeta) population in biological matrices using an immunoprecipitation-LC/MS assay.
Ford MJ; Cantone JL; Polson C; Toyn JH; Meredith JE; Drexler DM
J Neurosci Methods; 2008 Mar; 168(2):465-74. PubMed ID: 18187205
[TBL] [Abstract][Full Text] [Related]
18. The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Toropygin IY; Kugaevskaya EV; Mirgorodskaya OA; Elisseeva YE; Kozmin YP; Popov IA; Nikolaev EN; Makarov AA; Kozin SA
Rapid Commun Mass Spectrom; 2008; 22(2):231-9. PubMed ID: 18085519
[TBL] [Abstract][Full Text] [Related]
19. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry.
Portelius E; Westman-Brinkmalm A; Zetterberg H; Blennow K
J Proteome Res; 2006 Apr; 5(4):1010-6. PubMed ID: 16602710
[TBL] [Abstract][Full Text] [Related]
20. Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation.
Crouch PJ; Tew DJ; Du T; Nguyen DN; Caragounis A; Filiz G; Blake RE; Trounce IA; Soon CP; Laughton K; Perez KA; Li QX; Cherny RA; Masters CL; Barnham KJ; White AR
J Neurochem; 2009 Mar; 108(5):1198-207. PubMed ID: 19141082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
